Scilex Holding (SCLX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Scilex Holding's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Scilex Holding's ROA in the second quarter of 2026?
Scilex Holding Company recorded a cumulative net loss of $-449 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -152.44%.
However, within the Healthcare sector 808 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4426, from total ROA ranking in the first quarter of 2026 at 5183.
Scilex Holding Company Faces Financial Strain Amid New Study on ZTlido vs. Lidocaine PatchScilex Holding Company Announces Pain Medicine Study and Financial Challenges Palo Alto, CA – January 13, 2025 – Scilex Holding Company (Nasdaq: SCLX), a company dedicated to the development and commercialization of non-opioid pain management therapies, finds itself at a crucial juncture as it contends with severe financial losses alongside a significant study on its pain management product, ZTlido. This retrospective claims data analysis, recently published in Pain Medicine News, compares the effectiveness of ZTlido to the widely used lidocaine 5% patch, offering a critical look at the competitive landscape for pain management products.Despite the critical developments surrounding ZTlido, Scilex has seen its stock decline dramatically—down 79.36% from a year ago. This precipitous drop highlights the challenges the company faces in regaining market confidence. In the twelve-month period ending in the second quarter of 2024, Scilex recorded a staggering cumulative net loss of $119 million, which has resulted in a negative return on assets (ROA) of -131.67%. When measured against its peers in the healthcare sector, Scilex stands out for all the wrong reasons; 815 other companies report a higher return on assets, indicating a troubling trend for investors, stakeholders, and the company s overall viability.
PALO ALTO, Calif. Sept. 18, 2024 – Scilex Holding Company (Nasdaq: SCLX), an innovative revenue-generating organization dedicated to acquiring, developing, and commercializing non-opioid pain management products, recently made significant strides in the healthcare sector as outlined in its latest press release. These advancements include the continued partnership with Endeavor Distribution LLC to enhance commercial product offerings and the successful repayment of a $10 million loan from FSF 33433 LLC.Despite these promising developments, not all recent news has been favorable for Scilex. Following the announcement, the company’s stock witnessed a decline of 12%. Furthermore, the company’s financial standing raised concerns; it reported a cumulative net loss of $117 million over the twelve months leading up to the third quarter of 2023. This resulted in a concerning negative return on assets (ROA) of -126.16%, a statistic that positioned Scilex below 902 other companies within the healthcare sector that demonstrated a higher return on assets. Notably, however, Scilex’s overall ROA ranking showed a slight improvement, moving up from 4616 in Q2 2023 to 4560 by the end of September 2023.
Introduction Scilex Holding Company, a revenue-generating company dedicated to non-opioid pain management, has announced the appointment of Dr. Annu Navani to its Board of Directors. This move highlights the company s commitment to enhancing its capabilities in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. With previous financial challenges and a recent notice to lenders regarding short positions on restricted shares, it is crucial to delve into the facts and assess their impact on Scilex Holding Company s future. Scilex Holding Company s Financial Performance During the 12 months ending in the third quarter of 2023, Scilex Holding Company reported a cumulative net loss of $-117 million. This has resulted in a negative return on assets (ROA) of -126.16%. While these figures indicate financial difficulties for the company, the appointment of Dr. Annu Navani demonstrates its determination to turn its fortunes around.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
